United States Sunesis Tender

Sunesis Pharmaceuticals Inc. announced it will provide a program update for vecabrutinib the Companys oral reversible non-covalent BTK inhibitor which is currently being evaluated in an ongoing Phase 1b2 clinical trial in adults with relapsed chronic lymphocytic leukemia CLL and other B-cell malignancies. The program will include data presented in the poster titled Preliminary Safety Pharmacokinetic and Pharmacodynamic Results from a Phase 1b2 Dose Escalation and Cohort-Expansion Study of the Noncovalent Reversible Brutons Tyrosine Kinase Inhibitor BTKi Vecabrutinib in B-Lymphoid Malignancies Abstract No 3141. This update will take place at a dinner event hosted by Sunesis during the 60th American Society of Hematology ASH Annual Meeting and Exposition on Sunday December 2 2018 at 800 p.m. PT.Sunesis executive management team will present an update on vecabrutinib from the ongoing Phase 1b2 dose-escalation study evaluating the safety pharmacokinetics pharmacodynamics and antitumor activity of vecabrutinib in B-lymphoid malignancy patients with prior BTK therapy. The Phase 1b2 trial is an open-label sequential-group study that is enrolling patients across eight leading sites in the United States.The event will also feature a discussion with a key opinion leader in CLL William G. Wierda M.D. Ph.D. Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center. Dr. Wierda is one of the principal investigators of Sunesis ongoing vecabrutinib trial.The event on December 2 will begin at 800 p.m. PT and is intended for institutional investors and sell-side analysts only. Please contact maeve@argopartners.com for more information. A live webcast of the event with slides will be available on the Investors section of the Sunesis website at www.sunesis.com beginning at approximately 830 p.m. PT and will be subsequently archived for 90 days.